-
-
-
-
-
-
-
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
vTv Therapeutics begins Phase 3 trial for type 1 diabetes treatment
-
-
-
-
-
-
-
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
-
-
-
-
-
-
-
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
-
-
-
-
-
-
-
vTv Therapeutics (VTVT) Sells $4.4M of Reneo Pharmaceuticals Shares
-
-
-
-
-
-
-
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
-
1,154,873 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

